



Contents lists available at ScienceDirect

Preventive Medicine

journal homepage: www.elsevier.com/locate/ypmed

Commentary

A lifestyle program of exercise and weight loss is effective in preventing and treating type 2 diabetes mellitus: Why are programs not more available? ☆

Philip A. Ades *

University of Vermont College of Medicine, Division of Cardiology, Burlington, VT 05401, USA

ARTICLE INFO

Available online xxxx

Keywords:

Type 2 diabetes mellitus
Prevention
Treatment
Exercise training
Weight loss

ABSTRACT

There is substantial evidence that type 2 diabetes mellitus (T2DM) can be prevented in high-risk individuals by a lifestyle program of regular exercise and weight reduction. Additionally, there is emerging evidence that new onset T2DM (<1 year) can go into remission after weight loss and exercise in a majority of motivated individuals, obviating a need for glucose lowering medications. Yet, lifestyle programs to support such behavior change are not widely available. Moreover, health care insurance companies generally do not provide coverage for behavioral weight loss programs to prevent or treat T2DM. Consequently, physicians caring for individuals with T2DM may find it much easier to start a chronic glucose lowering medication rather than attempting to motivate and support patients through long-term behavior change. The cardiac rehabilitation model of disease management, with a network of over 2000 programs in the U.S., is well suited to deliver medically-supervised lifestyle programs. National organizations such as the American Diabetes Association and the American Association of Cardiovascular and Pulmonary Rehabilitation should support greater availability and use of lifestyle programs for T2DM treatment and prevention.

© 2015 Elsevier Inc. All rights reserved.

In 2012 the prevalence of diabetes in the U.S. approached 26 million individuals with an annual incidence of over 2 million new cases (Geiss et al., 2014). Diabetes was the 7th leading cause of death in the U.S. in 2010 and its diagnosis approximately doubles individual medical costs (Roglic et al., 2005; Centers for Disease Control and Prevention, 2014). Its increasing incidence has paralleled the obesity epidemic (Geiss et al., 2014) thus its origin has a strong behavioral component.

There is substantial evidence that type 2 diabetes mellitus (T2DM) can be prevented in high-risk individuals with a program of exercise and behavioral weight loss (“lifestyle program”) (Knowler et al., 2002; Tuomilehto et al., 2001). In the Diabetes Prevention Program a lifestyle program of at least 150 min per week of physical activity and a behavioral weight loss program aiming to reduce body weight by 7% was applied to overweight, glucose intolerant individuals at high risk for the development of T2DM (Knowler et al., 2002). Compared with placebo, over a follow-up period of 2.8 years, the lifestyle intervention reduced the incidence of T2DM by 58%. To prevent one case of T2DM over a period of 3 years, just 6.9 persons would have to participate in the lifestyle-intervention program.

☆ Preparation of this paper was supported in part by a Centers of Biomedical Research Excellence P20GM103644 award from the National Institute on General Medical Sciences.

* Corresponding author at: Cardiac Rehabilitation and Prevention, University of Vermont Medical Center, 62 Tilley Dr., S. Burlington VT 05403, USA.

E-mail address: Philip.ades@vtmednet.org.

A study from Finland found similar results (Tuomilehto et al., 2001). Subjects in the lifestyle intervention received dietary counseling to change the quality and quantity of their diet along with counseling to increase physical activity. After 4 years, the risk of developing T2DM was again reduced by 58%, leaving little doubt that this costly and disabling disease can be prevented or postponed by a formal lifestyle program of exercise and weight loss.

One would assume that pursuant to these well publicized findings, medical care systems in the U.S. and elsewhere would have put programs into place to obtain these same benefits in the clinical setting, as has been the case with cardiac rehabilitation programs for coronary artery disease. However, such has not been the case. Cost effectiveness analysis suggests that the lifestyle intervention to prevent T2DM is cost-effective compared either with no intervention or with metformin medical therapy (Diabetes Prevention Program Research Group, 2003; Herman et al., 2005). Yet, particularly in the U.S., physicians rarely have the option of referring appropriate patients to a formal diabetes prevention program and third party insurance coverage is rarely provided, effectively putting comprehensive clinical implementation on the back shelf. While there has been some success establishing low cost “out of pocket” programs through community centers and YMCA's, this approach is unlikely to provide widely available comprehensive coverage (Krukowski et al., 2013; Bozack et al., 2014).

If pre-diabetes or insulin resistance syndrome is left untreated, T2DM will develop in 11–23% of high risk individuals over a period of

2.8–4 years (Knowler et al., 2002; Tuomilehto et al., 2001). At the time when T2DM is initially diagnosed, selected individuals may be highly motivated to undertake a “last chance” lifestyle program given that the competing option is the cost and daily discomfort of medical therapy and frequent glucose monitoring. Is it then too late for lifestyle therapy to be effective?

The evidence that recently diagnosed T2DM can be put into remission (partial or complete) is less strong than the evidence for its prevention. Partial remission of T2DM is defined as HbA1c of 5.7%–6.5% whereas a complete remission was defined as an HbA1c of <5.7% (Buse et al., 2009). In the Look AHEAD study of combined weight loss and exercise in over 5000 individuals with T2DM, which achieved a mean weight loss of 8.6% and a fitness improvement of 21%, the partial remission rate at 1-year was only 11.5% (Gregg et al., 2012). However, the mean duration of T2DM from the time of diagnosis in this study was 5 years. In a subset of individuals with T2DM of less than 2 years duration, the combined remission rate increased to 22%. Factors associated with remission (mostly partial) included a shorter duration of T2DM, lower baseline HbA1c, no insulin therapy and greater weight loss. Unfortunately, there are remarkably little data describing the benefits of weight loss and exercise for individuals with recently diagnosed (<1 year) T2DM. Thus, the effectiveness of a comprehensive behavioral weight loss program at the time of initial diagnosis of T2DM is not well known.

In a small, recent, non-randomized study of weight loss and exercise in individuals with recently diagnosed (<1 year, mean 3.1 ± 3.8 months) T2DM, naive to metformin therapy, subjects lost a mean of 9.7 ± 5.2 kg and improved aerobic fitness by 18% (Ades et al., 2015). Although 2 subjects withdrew for unrelated medical reasons, 8 of 10 completers (80%) went into partial T2DM remission with the mean HbA1c decreasing from 6.8 ± 0.2 to $6.2 \pm 0.3\%$. This study implies that the one-year remission rate for recent onset T2DM may be higher than that found in the Look AHEAD study if the intervention is undertaken at the time of diagnosis of T2DM rather than years later. This, however, has not been established in a randomized controlled trial setting.

The American Diabetes Association/European Association SD treatment algorithm for new T2DM states that “at diagnosis, highly motivated patients with a HbA1c level of <7.5% should be given the opportunity to engage in lifestyle changes for 3–6 months before embarking on pharmacotherapy (usually metformin)” (Nathan et al., 2009). In the clinical setting, however, less than 40% of patients with T2DM even see a Certified Diabetes Educator for 1–3 sessions prior to the institution of glucose lowering medications much less embark upon a serious and intense long-term program of exercise and weight loss (Kennedy et al., 2005). This contrasts with the situation for patients with new onset coronary artery disease where insurance coverage for cardiac rehabilitation programs in the U.S. is almost universal, programs are widely available (>2000 certified programs throughout U.S.) and hundreds of thousands of patients participate annually (Ades, 2001).

For lifestyle treatment programs to be more widely available for individuals at risk of or recently diagnosed with T2DM, consideration should be given for such programs to be delivered at certified cardiac rehabilitation programs (Curnier et al., 2005). These programs are staffed by physicians, nurses, exercise physiologists, dietitians and other health care professionals and highly capable at delivering safe and effective exercise and weight loss programs (Ades, 2001; Balady et al., 2007; Ades et al., 2009). Over a period of 36 sessions of exercise training and counseling delivered over a 3–4 month period, mean fitness increases by 17% (Ades et al., 2006). Furthermore, when behavioral weight loss counseling is provided to overweight patients in cardiac rehabilitation, a mean weight loss of 3.7–8.2 kg is attained along with a significant increase in insulin sensitivity (Ades et al., 2009). Cardiac rehabilitation programs have been shown to be cost-effective when compared to other treatments for coronary heart disease second only to smoking cessation counseling (Ades et al., 1997). Referral and medical communication processes have already been established between primary care

providers and cardiac rehabilitation programs and in the hypothetical situation where new-onset T2DM becomes a qualifying diagnosis, referral of well-motivated patients would be straightforward.

In the absence of cardiac rehabilitation type coverage for new onset T2DM, an alternative approach is suggested by the 2011 Center for Medicare Services favorable coverage determination for intensive behavioral therapy for obesity treatment in the primary care setting for individuals with a BMI > 30 kg/m² (<http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAIAAA&NCAId=253&>). For diabetes prevention, or treatment of new T2DM in the Medicare age group, intensive behavioral therapy supplemented by a home walking program should be considered although the absence of a supervised exercise program may be a limitation.

Physicians caring for individuals with new onset T2DM should consider changing their approach to treatment of new T2DM, as motivating the initiation of significant behavior change can be more complex and time consuming than simply prescribing a pill. Working collaboratively, however, primary care physicians and cardiac rehabilitation professionals have the influence, expertise and experience to provide lifestyle programs to optimally treat individuals with, or at high risk for developing T2DM. Organizations such as the American Diabetes Association and the American Association of Cardiovascular and Pulmonary Rehabilitation should individually and collaboratively support efforts to make lifestyle treatment programs T2DM more widely available.

Conflict of interest statement

The author has no conflict of interest to report.

Acknowledgment

The author thanks Patrick Savage MS for his helpful review of this manuscript.

References

- Ades, P.A., 2001. Cardiac rehabilitation and the secondary prevention of coronary heart disease. *N. Engl. J. Med.* 345, 892–902.
- Ades, P.A., Pashkow, F., Nestor, J., 1997. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. *J. Cardpulm. Rehabil.* 17, 222–231.
- Ades, P.A., Savage, P.D., Brawner, C.A., Lyon, C.E., Ehrman, J.K., Bunn, J.Y., Keteyian, S.J., 2006. Aerobic capacity in patients entering cardiac rehabilitation. *Circulation* 113, 2706–2712.
- Ades, P.A., Savage, P.D., Toth, M.J., Harvey-Berino, J., Schneider, D.L., Bunn, J.Y., et al., 2009. High-caloric expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. *Circulation* 119, 2671–2678.
- Ades, P.A., Savage, P.D., Marney, A.M., Harvey, J., Evans, K.A., 2015. Remission of recently diagnosed type 2 diabetes mellitus with weight loss and exercise. *J. Cardpulm. Rehabil. Prev.* (Jan 29. [Epub ahead of print]).
- Balady, G.J., Williams, M.A., Ades, P.A., Bittner, V., Comoss, P., Foody, J., Franklin, B.A., Sanderson, B.K., Southard, D., 2007. AHA/AACVPR core components of cardiac rehabilitation/secondary prevention programs. *Circulation* 115, 2675–2682.
- Bozack, A., Millstein, S., Garcel, J.M., Kelly, K., Ruberto, R., Weiss, L., 2014. Implementation and outcomes of the New York State YMCA diabetes prevention program: a multisite community-based translation, 2010–2012. *Prev. Chron. Dis.* 11, E115.
- Buse, J.B., Caprio, S., Cefalu, W.T., Ceriello, A., Del Prato, S., Inzucchi, S.E., et al., 2009. How do we define cure of diabetes? *Diabetes Care* 32, 2133–2135.
- Centers for Disease Control and Prevention, 2014. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. US Department of Health and Human Services, Atlanta, GA.
- Curnier, D., Savage, P.D., Ades, P.A., 2005. Geographic distribution of cardiac rehabilitation programs in the U.S. *J. Cardpulm. Rehabil.* 25, 80–84.
- Diabetes Prevention Program Research Group, 2003. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. *Diabetes Care* 26, 2518–2523.
- Geiss, L.S., Wang, J., Cheng, Y.L., Thompson, T.J., Barker, L., Li, Y., Albright, A.L., Gregg, E.W., 2014. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. *JAMA* 312, 1218–1226.
- Gregg, E.W., Chen, H., Wagenknecht, L.E., Clark, J.M., Delahanty, L.M., Bantle, J., et al., 2012. Association of an intensive lifestyle intervention with remission of type 2 diabetes. *JAMA* 308, 2489–2496.
- Herman, W.H., Hoerger, T.J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R.F., Ackermann, R.T., Engelgau, M.M., Ratner, R.E., 2005. Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in

- preventing type 2 diabetes in adults with impaired glucose tolerance. *Ann. Intern. Med.* 142, 323–332.
<http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=Intensive%20Behavioral%20Therapy%20for%20Obesity&bc=ACAAAAAIAAA&NCAId=253&>.
- Kennedy, A.G., MacLean, C.D., Littenberg, B., Ades, P.A., Pinckney, R.G., 2005. The challenge of achieving national cholesterol goals in patients with diabetes. *Diabetes Care* 2, 1029–1034.
- Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M., 2002. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* 346, 393–403.
- Krukowski, R.A., Pope, R.A., Love, S., Lensing, S., Felix, H.C., Prewitt, T.E., West, D., 2013. Examination of costs for a lay health educator-delivered translation of the Diabetes Prevention Program in senior centers. *Prev. Med.* 57, 400–402.
- Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., Zinman, B., 2009. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 32, 193–203.
- Roglic, G., Unwin, N., Bennett, P.H., Mathers, C., Tuomilehto, J., Nag, S., Connolly, V., King, H., 2005. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care* 28, 2130–2135.
- Tuomilehto, J., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., Uusitupa, M., 2001. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N. Engl. J. Med.* 344 (18), 1343–1350 (May 3).